USP18 modulates lupus risk via negative regulation of interferon response

3

4 Krista Freimann^{1,2}, Anneke Brümmer^{3,4}, Robert Warmerdam^{5,6}, Tarran S Rupall^{2,7}, Ana Laura

5 Hernández-Ledesma⁸, Joshua Chiou⁹, Emily R. Holzinger¹⁰, Joseph C. Maranville¹⁰, Nikolina

6 Nakic¹¹, Halit Ongen¹², Luca Stefanucci^{2,7}, Michael C. Turchin¹⁰, eQTLGen Consortium[†], Luce

7 Franke^{5,6}, Urmo Võsa¹³, Carla P Jones^{2,7}, Alejandra Medina-Rivera⁸, Gosia Trynka^{2,7}, Kai

- 8 Kisand¹⁴, Sven Bergmann^{3,4,15}, Kaur Alasoo^{1,2*}
- 9
- 10 1. Institute of Computer Science, University of Tartu, Tartu, Estonia
- 11 2. Open Targets, South Building, Wellcome Genome Campus, Hinxton, Cambridge, UK
- 12 3. Department of Computational Biology, University of Lausanne, Switzerland
- 13 4. Swiss Institute of Bioinformatics, Lausanne, Switzerland
- 14 5. Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the
- 15 Netherlands
- 16 6. Oncode Institute, Amsterdam, the Netherlands
- 17 7. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK
- 18 8. Laboratorio Internacional de Investigación Sobre el Genoma Humano, Universidad Nacional Autónoma
- 19 de México, Santiago de Querétaro, Mexico
- 20 9. Internal Medicine Research Unit, Research and Development, Pfizer, Cambridge, MA, USA
- 21 10. Bristol Myers Squibb, Cambridge, Massachusetts, USA
- 22 11. Research Technologies, GSK, Stevenage, UK
- 23 12. Research Technologies, GSK, Heidelberg, Germany
- 24 13. Institute of Genomics, University of Tartu, Tartu, Estonia
- 25 14. Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Estonia
- 26 15. Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa
- [†]A list of authors and affiliations for the eQTLGen Consortium is listed in the Supplementary
- 28 Materials.
- 29 *Corresponding author. Email: kaur.alasoo@ut.ee

30 Abstract

- 31 Although genome-wide association studies have provided valuable insights into the genetic
- 32 basis of complex traits and diseases, translating these findings to causal genes and their
- 33 downstream mechanisms remains challenging. We performed *trans* expression quantitative trait
- 34 locus (*trans*-eQTL) meta-analysis in 3,734 lymphoblastoid cell line samples, identifying four
- 35 robust loci that replicated in an independent multi-ethnic dataset of 682 individuals. One of
- 36 these loci was a missense variant in the ubiquitin specific peptidase 18 (USP18) gene that is a
- 37 known negative regulator of interferon signalling and has previously been associated with
- 38 increased risk of systemic lupus erythematosus (SLE). In our analysis, the SLE risk allele
- 39 increased the expression of 50 interferon-inducible genes, suggesting that the risk allele impairs
- 40 USP18's ability to effectively limit the interferon response. Intriguingly, most *trans*-eQTL targets

of USP18 lacked independent *cis* associations with SLE, cautioning against the use of *trans*eQTL evidence alone for causal gene prioritisation.

43 Introduction

44 Genome-wide association studies (GWAS) have provided valuable insights into the genetic 45 basis of complex traits and diseases. However, translating GWAS findings to actionable drug 46 targets has remained challenging, particularly when the functions of the associated genes are 47 unknown. A promising technique to identify the effector genes of GWAS variants as well as their 48 downstream regulatory consequences is trans gene expression and protein quantitative trait loci 49 (trans-QTL) analysis. Trans-QTL studies test for association between genetic variants across the genome and expression levels of all measured genes or proteins¹. In a prominent example, 50 an erythrocyte-specific regulatory element first identified as a trans protein QTL (trans-pQTL) for 51 52 foetal haemoglobin (HbF) was used to design the first ever gene editing therapy for sickle-cell disease^{2,3}. 53

54

55 *Trans*-QTLs are especially promising, because 60%-90% of gene and protein expression

heritability is located in $trans^4$, most associations detected in large-scale pQTL studies are

57 located in *trans*⁵, and *cis*-QTL discovery is starting to saturate after 10,000 samples⁵.

58 Furthermore, most complex trait heritability has been proposed to be mediated by *trans*-QTL

⁵⁹ effects⁴. However, current large-scale *trans*-eQTL and *trans*-pQTL studies have been limited to

60 easily accessible bulk tissues such as whole $blood^{6,7}$ or plasma^{5,8–10}. Bulk tissue studies are

61 subject to cell type composition effects which can be difficult to distinguish from true intracellular 62 trans-QTLs^{1,6}. The whole blood and plasma studies are also likely to miss cell type and context

63 specific regulatory effects. In contrast, *trans*-eQTL studies in other tissues and purified cell types

64 have had limited statistical power due to small sample sizes (typically less than one thousand

samples), enabling the discovery of only very large effects and potentially underestimating

66 pleiotropic effects on multiple target genes¹¹⁻¹⁸.

67

68 A key limitation in our understanding of how *trans*-eQTLs contribute to complex traits and how 69 they interact with *cis*-eQTL is the lack of well-characterised disease-associated *trans*-eQTL

⁷⁰ signals⁴. Two most prominent examples include the adipose-specific *KLF14* locus associated

71 with type 2 diabetes^{16,19} and the IRX3/5 locus associated with obesity^{20,21}. At the *KLF14* locus,

the lead variant (rs4731702) is a *cis*-eQTL for the *KLF14* transcription factor and was

associated with the expression of 385 target genes in *trans*, 18 of which also had independent

cis associations for other metabolic traits¹⁹. The simultaneous regulation of multiple target genes

in *trans*-eQTL regulatory networks seems to be a general property of many known *trans*-eQTL
 signals^{6,12,14}. However, what proportion of *trans*-eQTL target genes directly mediate the disease

76 signals 77. However, what proportion of *trans*-eQ1L target genes directly mediate the disease 77 or trait associations as opposed to being independent 'bystanders' with minimal direct causal

- 78 effect has remained unclear.
- 79

80 We performed the largest *trans*-eQTL meta-analysis in a single cell type, comprising 3,734

81 lymphoblastoid cell line (LCL) samples across nine cohorts (MetaLCL). LCLs are obtained by

82 transforming primary B-cells with Epstein-Barr virus²². LCLs have been widely used as a

resource for human genetics, from banking cells from rare genetic disorders, through control 83 84 material in laboratories to prevent repetitive blood sampling, to the study of tumorigenesis, mechanisms of viral latency and immune evasion²². Furthermore, Epstein-Barr virus has been 85 epidemiologically linked to several autoimmune diseases in which B cells are implicated to play 86 a pathogenic role, such as multiple sclerosis (MS)^{23,24} and systemic lupus erythematosus 87 (SLE)²⁵ with recent studies starting to elucidate the potential molecular mechanisms underlying 88 these associations²⁶⁻²⁸. Thus, *trans*-eQTLs discovered in LCLs might provide insights into the 89 90 pathogenesis of these autoimmune diseases. 91 92 After stringent quality control, we identify four highly robust trans-eQTL associations that 93 replicate in an independent cohort (n=682) and are associated with multiple target genes. One 94 of these signals corresponds to a missense variant in the USP18 gene and is also associated 95 with increased risk of SLE. The SLE risk allele is associated with increased activity of the type I 96 interferon signalling pathway and increased expression of several classical interferon response 97 genes. While there is robust evidence for the potential causal role of increased interferon 98 signalling in SLE pathogenesis, we find that the expression of most individual interferon 99 response genes is unlikely to have a direct causal effect on SLE. Our results caution against 100 blindly using trans-QTL associations for target gene prioritisation without clear understanding of 101 the trans-QTL mechanism and robust genetic evidence from cis-acting variants implicating the 102 same gene. To support secondary use of our data, we have made the complete MetaLCL trans-103 eQTL summary statistics for 18,792 genes publicly available via the eQTL Catalogue FTP 104 server.

105 Results

106 Large-scale trans-eQTL meta-analysis in a single cell type

107 We performed a large-scale trans-eQTL meta-analysis, utilising data from LCLs collected from

108 3,734 donors across nine cohorts of European ancestries (Table S1). After excluding *cis*

- associations located within 5 Mb of the target gene, we identified 79 suggestive independent
- 110 *trans*-eQTL loci at p-value < 1×10^{-11} threshold (Figure 1). To identify robust signals associated
- with multiple target genes and reduce the risk of false positives caused by cross-mappability²⁹,
- we further required each locus to be associated with at least five independent target genes (p < 5×10^{-8}) with low cross-mappability scores (see Methods). This filtering reduced the number of
- 5x10⁻⁸) with low cross-mappability scores (see Methods). This filtering reduced the number of
- candidate loci to six (Figure 1), four of which replicated in an independent multi-ethnic cohort of
- 682 individuals³⁰. These four replicating *trans*-eQTL loci were located near the *BATF3*, *MYBL2*,
 USP18, *HNF4G* genes (Table S2, Figure S2). While the strong *trans*-eQTL signal near the
- 117 BATF3 transcription factor (2294 targets at FDR 5%) has been previously reported³¹, the other
- three seem to be novel. Remarkably, the *trans*-eQTL targets at the *MYBL2* locus were
- 119 consistent with direct activation by the MYBL2 transcription factor (Supplementary Note),
- 120 indicating that our analysis is identifying biologically interpretable signals.







128 Missense variant in USP18 affects lupus risk via negative regulation of

- 129 interferon response
- 130 For the four high-confidence loci, we performed GWAS lookup using the Open Targets Genetics
- 131 Portal³². We found that our *trans*-eQTL lead variant in the USP18 locus (chr22_18166589_T_C,
- rs4819670) was shared with a GWAS lead variant identified for SLE in East Asians³³. Using the
- point estimation of colocalisation (POEMColoc) method, we also confirmed that the two signals
- 134 colocalised (PP4 = 0.97) (Figure 2A)³⁴. At this locus, we identified 40 *trans* target genes at FDR
- 135 5% that were all strongly enriched for Reactome interferon signalling (R-HSA-913531, $p = 100^{20}$
- 136 1.1×10^{-26}) and interferon alpha/beta signalling (R-HSA-909733, p = 1.7×10^{-21}) pathways. The
- rs4819670-C allele was associated with decreased expression of multiple canonical type I
 interferon response genes (e.g. *ISG15*, *IFI44*, *OAS1-3*) (Figure 2B). Reassuringly, we observed
- 139 consistent effect sizes across nine sub-cohorts in our meta-analysis (I^2 heterogeneity statistic =
- 140 0.46, Figure S2). USP18 is a known negative regulator of interferon signalling and a rare loss-
- 141 of-function mutation in USP18 causes severe type I interferonopathy (Figure 2C)^{35,36}. The
- 142 rs4819670-C was also associated with decreased risk of systemic lupus erythematosus (SLE) in
- 143 East Asians³³. Furthermore, the rs4819670 lead variant is in perfect linkage disequilibrium (LD)
- 144 $(r^2 = 1, 1000 \text{ Genomes EAS superpopulation})$ with a USP18 missense variant rs3180408

- (chr22_18167915_C_T, ENSP00000215794.7:p.Thr169Met). While the GWAS association was
 previously known, it remained uncertain which allele of the missense variant rs3180408 was
- 147 more likely to decrease USP18 protein function, especially because the variant was predicted to
- be benign by all tested variant effect prediction tools available from Ensembl VEP³⁷. Our results
- suggest that the rs3180408-T SLE risk allele decreases USP18 protein function as USP18 is a
- 150 negative regulator of type I interferon response genes.151
 - C А Imputed SLE summary statistics (POEMColoc) rs4819670 10 -log10(p) 6 4 INF-I HERC5 trans-eQTL signal at USP18 locus rs4819670 rs3180408 10 **INF-I** receptor 1 PP4=0.97 8 -log10(p) **INF-I** receptor 2 6 1.81 Position 1.82 1.83 1.84 1e7 В USP41 25 ISG15 Not significant Down-regulated **Up-regulated** USP18 20 STAT1 15 -logFDR IRF9 10 JAK1 1F144 HERC5 CMPK2 PLSCR1 NT5C3A STAT2 OAS2 DDX60 1SG15 OASL IFITI IRF7 IFI44 ISG15 MXI EIF2AK2 OAS1 FI44L CIITA OAS1 IF135 RSAD2 UBE2L6 SP110 IFIT1 DDX60 OASL 0 HERC5 -0.3 0.0 effect size 0.1 0.2 0.3 -0.7



153 Figure 2. SLE GWAS association at the USP18 locus is a *trans*-eQTL for interferon

response genes. (A) Regional association plot for the SLE GWAS with POEMColoc imputed

summary statistics and regional association plot for the lead *trans*-eQTL gene (*HERC5*) at the
 USP18 locus. The *trans*-eQTL lead and GWAS lead variants (rs4819670, shown in blue) are

157 identical and in perfect LD with a missense variant (rs3180408, shown in red) in the USP18

158 gene. The original regional association plot for the SLE GWAS is shown on Figure S4. (**B**)

159 Volcano plot of the *trans*-eQTL target genes. (C) Schematic illustration of the role of USP18 in

160 the regulation of interferon response genes, adapted from Alsohime *et al*³⁶.

161 Role of aberrant interferon signalling in lupus pathogenesis

162 Several studies have suggested that causal GWAS genes are enriched in shared pathways or 163 biological processes^{38–40}. To further characterise the potential role of USP18 target genes in lupus, we performed additional trans-eQTL meta-analysis across the nine discovery cohorts and 164 165 one replication cohort (total n = 4.416). This increased the number of significant USP18 target 166 genes to 50 (FDR < 5%). Notably, 18/50 target genes overlapped the Reactome interferon 167 alpha/beta signalling (R-HSA-909733) pathway (hypergeometric test, $p = 4.14 \times 10^{-24}$) and 26/50 genes overlapped a consensus set of interferon response genes (n = 124) identified by 168 Mostafavi *et al*⁴¹ ($p = 1.44 \times 10^{-39}$, Table S4). Reassuringly, 39/50 genes were also more highly 169 expressed in peripheral blood mononuclear cells from SLE cases compared to controls⁴² (Table 170 S4), consistent with the established role of increased interferon signalling in SLE⁴³. 171 172

- 173 To better understand the role of the USP18 target genes in the interferon alpha/beta signalling
- pathway, we focussed on the 60 genes belonging to the Reactome R-HSA-909733 interferon
- alpha/beta signalling pathway and divided them into three categories category I: proteins
- 176 involved in signal transduction via IFNAR1/2 receptor (n = 13 genes, including the multi-gene
- interferon-alpha gene cluster, Figure 3A); category II: downstream transcriptional targets of the
 interferon signalling (38 genes from the Reactome R-HSA-1015702 sub-pathway, Figure 3B)
- and 3) and category III: other pathway genes (n = 9) not belonging to the first two categories
- 180 (Figure S5). We found that 16/50 USP18 targets overlapped with the 38 category II genes
- (transcriptional targets of interferon response) ($p = 1.18 \times 10^{-29}$). In contrast, only 2/50 USP18
- 182 trans-eQTL target genes (STAT1 and ISG15) overlapped the 13 category I genes (IFNAR1/2
- 183 receptor signal transduction proteins) and none overlapped the 9 category III genes. This
- 184 suggests that the USP18 *trans*-eQTLs are primarily capturing the transcriptional targets of
- 185 interferon response (category II), consistent with the established role of USP18 in regulating
- 186 these genes (Figure 2C)³⁶.
- 187

188 Next, we assessed if there were additional lupus GWAS signals overlapping the three 189 categories of interferon response genes defined above. We first used the Open Targets 190 Genetics portal to extract the prioritised target genes for 108 lupus GWAS loci from Yin et al^{33} . 191 This revealed that three prioritised genes (USP18, STAT1, IFNA1-17) overlapped with the 13 192 category I genes (IFNAR1/2 signal transduction proteins, Figure 3A) and four prioritised genes 193 (IRF1/5/8 and OAS1) overlapped with the 38 category II genes (transcriptional targets of 194 interferon response, Figure 3B). Out of these, IRF1/5/8 are themselves transcription factors involved in the regulation of interferon production^{44,45}, and stronger IRF1 binding across many 195 GWAS loci has been associated with higher Crohn's disease risk⁴⁶. Only OAS1 represents a 196 197 classical antiviral gene and here the GWAS lead variant is in perfect LD with a fine-mapped splice QTL for OAS1 in the eQTL Catalogue (Figure S6)⁴⁷. Interestingly, while the USP18 trans-198 199 eQTL risk allele increased OAS1 expression (Figure 3B), the cis splice QTL risk allele (rs10774671-A) increased the expression of a transcript with an alternative 3' end that was 200 associated with lower OAS1 protein abundance (Figure S6)^{48,49}, suggesting that *cis* and *trans* 201 202 effects on the OAS1 gene have opposite direction of effect on lupus risk. 203

204 We also overlapped interferon alpha/beta signalling pathway genes with ongoing or completed phase III clinical trials for SLE extracted from the ChEMBL database⁵⁰. We identified three 205 category I (interferon signal transduction) genes (IFNAR1, JAK1 and TYK2) that have been 206 207 targeted by a clinical trial for SLE (Figure 3A). While the trials targeting JAK1 and TYK2 are 208 currently ongoing, a randomised control trial of anifrolumab, a human monoclonal antibody to 209 type I interferon receptor subunit 1 (*IFNAR1*), found it to be an effective treatment for SLE^{51} . 210 None of the category II genes (transcriptional targets of interferon signalling, Figure 3B) and 211 category III genes (Figure S5) are currently in a phase III clinical trial for SLE (Figure 3B).

212

213 There is an emerging consensus that rare mutations in genes prioritised for autoimmune diseases from GWAS studies can often also cause primary immunodeficiencies (PIDs)^{52,53}. For 214 example, loss-of-function mutations in USP18 cause rare type I interferonopathy^{35,36}. At the 215 216 same time, GWAS studies for SLE and other autoimmune diseases are still only powered to 217 detect variants with large effects. Thus, knowing if a gene causes PID might be a useful (if 218 noisy) indicator that the same gene might be discovered in a future larger autoimmune GWAS 219 study. Thus, we obtained the list of genes causing either PID or monogenic inflammatory bowel disease from Genomics England⁵⁴ and overlapped those with the three categories of interferon 220 response genes defined above. We found that 10/13 category I genes (interferon signal 221 222 transduction) have previously been implicated in causing PID, including USP18 and all three 223 phase III drug candidates for SLE (Figure 3A). In contrast, only 8 of the 38 category II genes 224 (transcriptional targets of interferon response) have been implicated in PIDs (Figure 3B), 225 including OAS1 and IRF8 also detected by SLE GWAS. Finally, none of the category III genes 226 have been implicated in PIDs (Figure S5).

227

228 Triangulation of evidence from prioritised lupus GWAS target genes, phase III clinical trial 229 information and overlap with primary immunodeficiency genes highlights modulation of aberrant 230 interferon alpha/beta signalling in B-cells as an emerging therapeutic opportunity for SLE 231 (category I, Figure 3A). This is further supported by recent studies demonstrating that depleting autoreactive B-cells via anti-CD19 CAR T cell therapy is an effective therapy for SLE and other 232 autoimmune diseases^{55,56}. In contrast, most *trans*-eQTL targets of USP18 overlap 233 234 transcriptional targets of interferon response (category II, Figure 3B) and it is far less clear what 235 is the potential causal roles of these genes in SLE pathogenesis.

- 236 237
- 231
- 238
- 239
- 240



241

242 Figure 3. Role of interferon signalling in SLE pathogenesis. (A) Upstream regulators of interferon response genes (IFNA* contains multi-gene interferon-alpha gene cluster). (B) 243 244 Downstream transcriptional targets of the interferon signalling (HLA* marks the HLA region). 245 The increased gene expression is marked in red, while reduced gene expression is marked in blue. The visualisation illustrates the effect on USP18 target genes in relation to the SLE risk 246 allele. DE - differential gene expression in SLE cases versus controls⁴²; GWAS - GWAS hits for 247 SLE³³, ChEMBL, phase III - SLE phase III clinical trials from ChEMBL⁵⁰, PID - genes causing 248 primary immunodeficiency from Genomics England. 249

250 Replication of the USP18 trans-eQTL signal in whole blood

251 To understand the context-specificity of the USP18 trans-eQTL signal, we performed additional 252 replication in the eQTLGen Phase 2 trans-eQTL meta-analysis of up to 43,301 whole blood 253 samples. We observed that the USP18 missense variant rs3180408 was nominally associated 254 (p < 0.05) with the expression of 7/50 USP18 target genes, including our lead target gene 255 HERC5 (p = 0.037) as well as canonical interferon response genes IFI44 and ISG15 (Table S5). 256 For 6/7 nominally significant associations, the effect direction was concordant between the LCL 257 and whole blood meta-analyses, but the effect size was an order of magnitude smaller in whole 258 blood (Table S5). Thus, even at this very large sample size, the USP18 trans-eQTL signal 259 would not have been discovered in whole blood.

260

261 To understand the potential reasons for the attenuated effect in whole blood, we compared the 262 expression level of the USP18 gene across 49 GTEx tissues. We found that USP18 had the 263 highest expression in LCLs (median transcripts per million (TPM) = 45.3) and one of the lowest 264 in whole blood (median TPM = 0.46). Since USP18 is itself an interferon response gene and 265 LCLs are characterised by a strong interferon signature driven by active infection with the 266 Epstein-Barr virus, we characterised the expression of USP18 in naive B-cells as well as B-cells 267 stimulated with interferon-alpha and TLR7/8 agonist R848 for 16, 40 and 64 hours. We found 268 that the expression level of USP18 in B-cells was upregulated by ~3.5-fold after 16 hours of 269 stimulation and stayed elevated for at least 64 hours (Figure S7). This suggests that the very 270 strong active interferon signalling and associated upregulation of USP18 transcription in LCLs is 271 required for the *trans*-eQTL signal to be detected.

272 Discussion

273 We performed the largest *trans*-eQTL study in a single cell type where we profiled the 274 expression of 18,792 genes in 3,737 individuals from nine cohorts. We then replicated these 275 findings in an independent multi-ancestry LCL cohort of 682 individuals. After careful quality control, we identified six independent loci that were associated with five or more target genes, 276 277 and that were unlikely to be driven by cross-mappability artefacts. While we primarily focussed 278 on the SLE-associated rs3180408 missense variant in the USP18 gene in our analysis, we have 279 publicly released the complete genome-wide summary statistics from our MetaLCL project via 280 the eQTL Catalogue FTP server. In addition to disease-specific colocalisation applications, we 281 expect that our summary statistics will motivate the development and application of novel

- summary-based aggregative *trans*-eQTL mapping methods^{57–59}.
- 283

284 Despite the strong evidence for the critical role of type I interferon response in SLE

pathogenesis^{42,43} and three active clinical trials, we were surprised to see that of the 50 USP18

- target genes, only OAS1 had an independent *cis*-association with SLE. Expanding the analysis
- to interferon response genes from Reactome further implicated IRF1/5/8 genes and the HLA
- region, but most interferon response genes were not detected in the SLE GWAS. One potential
- explanation for this could be the limited statistical power of the SLE GWAS that profiled 13,377
- 290 cases and 194,993 controls, identifying a total of 113 loci³³. Furthermore, Liu *et al* demonstrated

that if multiple effector genes ('core' genes) are co-regulated by shared *trans* factors, with
shared directions of effects (which seems to be the case for the interferon response genes),
then nearly all heritability would be due to *trans* effects, further reducing the power to detect *cis*acting signals at individual target genes⁴.

295

296 However, interferon response involves rapid upregulation of a broad transcriptional regulatory 297 network of genes with diverse biological functions, only a subset of which might have a direct 298 causal effect on SLE. This is supported by the fact that among the 38 interferon response genes 299 (category II), only OAS1, ADAR, PSMB8, SAMHD1 and the IRF transcription factors have been 300 implicated in causing primary immunodeficiencies (Figure 3B). The remaining interferon 301 response genes might thus be better thought of as biomarkers of the complex effect of interferon signalling on multiple parts of the immune system^{43,60}. This could also help to explain 302 the apparent directionally discordant *cis* and *trans* effects for the OAS1 gene, raising an 303 304 intriguing possibility that to reduce lupus risk it might be important to have high baseline levels of OAS1 (to possibly aid with viral clearance⁴⁹) rather than increase its expression long term 305 306 after activation of interferon signalling. Similarly, it has been previously shown that variants in 307 the IL6R region that are associated with circulating C-reactive protein (CRP) concentrations, are also associated with coronary artery disease (CAD) risk⁶¹, but variants in the CRP region are 308 not⁶². Thus, plasma levels of CRP do not seem to have a direct causal effect on CAD risk, but 309 can still act as a molecular readout (biomarker) of the IL6R-mediated inflammatory response 310 that does seem to have a causal effect⁶³. These observations suggest that widespread 311 312 horizontal pleiotropy in gene regulatory networks could be a general property of trans-QTLs and 313 could help explain why using trans-pQTL signals in Mendelian randomisation analysis has had low specificity for identifying known drug targets^{64,65}. Instead, we propose that target genes 314 315 identified from large-scale trans-QTL studies could be better thought of as drug response 316 biomarkers for drugs targeting the *cis* gene responsible for the *trans* association⁸. 317

318 A limitation of our *trans*-eQTL analysis is its susceptibility to cross-mappability artefacts (Table 319 S3). While heuristic approaches have been developed to filter such artefacts post hoc, these 320 approaches are not guaranteed to remove all cross-mappability effects and might be too 321 conservative at other loci²⁹. Cross-mappability artefacts also tend to replicate well in independent cohorts²⁹. Furthermore, as the sample size of *trans*-eQTL studies increases, the 322 323 power to detect subtle cross-mappability effects as putative trans-eQTLs also increases. To 324 avoid these false positives, we used a very conservative strategy of requiring each trans-eQTL 325 locus to have at least five independent target genes that all pass the cross-mappability filter. As 326 a result, we likely missed many true trans-eQTLs regulating single or few target genes (e.g. 327 trans-eQTL effect near the CIITA transcription factor on multiple HLA genes that has been replicated in several independent studies^{6,31,66–68}, Table S2). Future large-scale *trans*-eQTL 328 studies will likely require the development of novel methods to properly adjust for cross-329 330 mappability, such as explicit modelling of transcript compatibility read counts between *cis* and 331 trans *target* genes⁶⁹. 332

While large-scale *trans*-eQTL studies using both bulk and single-cell measurements are likely to continue for easily accessible tissues such as whole blood (e.g. eQTLGen Phase 2⁷⁰), it seems

unlikely that we will be able to perform *trans*-eQTL studies comprising tens of thousands of

individuals for all disease-relevant cell types and contexts. A promising alternative is to use

337 arrayed CRISPR screens or single-cell approaches to identify downstream gene-regulatory

338 effects of disease-associated genes or individual genetic variants^{39,71,72}.

339 Methods

340 Datasets, samples and ethics

We used genotype and gene expression data from ALSPAC^{31,73,74}, TwinsUK⁷⁵, CoLaus^{76,77}, 341 GEUVADIS⁷⁸, MRCA⁷⁹, MRCE⁷⁹, GENCORD⁸⁰, GTEx v8¹⁷ and CAP⁸¹ studies. For replication, 342 we used data from the MAGE cohort³⁰. The RNA sequencing and genotype data from the 343 344 GEUVADIS and MAGE studies was publicly available as part of the 1000 Genomes project. For 345 the other studies, we applied for access to individual-level data via relevant data access 346 committees (DACs), explaining the aim of our project and the intent to publicly share meta-347 analysis summary statistics. Informed consent was obtained when research participants joined 348 the ten studies listed above. The use of the CAP data for this project was approved by the 349 National Heart, Lung and Blood Institute DAC. The use of the GTEx data for this project was 350 approved by the National Human Genome Research Institute DAC. The use of the GENCORD 351 data for this project was approved by the GENCORD DAC. The use of the MRCA and MRCE 352 data for this project was approved by the Gabriel Consortium DAC. The use of TwinsUK data for 353 this project was approved by the TwinsUK Resource Executive Committee. The use of the ALSPAC data for this project was approved by the ALSPAC Executive Committee. For the 354 355 ALSPAC cohort, ethical approval for the study was obtained from the ALSPAC Ethics and Law 356 Committee and the Local Research Ethics Committees. Consent for biological samples has 357 been collected in accordance with the Human Tissue Act (2004). The CoLaus study was 358 approved by the Institutional Ethics Committee of the University of Lausanne. 359 Single-cell RNA-seq samples were sourced ethically, and their research use was in accord with 360 the terms of informed consent under an institutional review board/ethics committee-approved 361 protocol (UK Regional Ethics Committee approval granted to work at Wellcome Sanger Institute, protocol reference number 15/NW/0282; project was approved by the Ethics on Research 362 Committee of the Institute of Neurobiology at Universidad Nacional Autonoma de Mexico 363 364 (UNAM), with the approval number 110.H.).

365 Genotype data quality control and imputation

366**Pre-imputation quality control.** Genotype imputation was performed as described367previously47. Briefly, we lifted coordinates of the genotyped variants to the GRCh38 build with368CrossMap v0.4.182. We aligned the strands of the genotyped variants to the 1000 Genomes 30x369on GRCh38 reference panel83 using Genotype Harmonizer84. We excluded genetic variants with370Hardy-Weinberg p-value < 10-6, missingness > 0.05 and minor allele frequency < 0.01 from</td>371further analysis. We also excluded samples with more than 5% of their genotypes missing.372

Genotype imputation and quality control. Most of the datasets were imputed using the 1000
 Genomes reference panel based on the GRCh38 genome version. CoLaus dataset was
 imputed using the TOPMed Imputation Server^{85–87}, while still aligning with the same reference
 genome version. Additionally, GEUVADIS, GTEx and MAGE cohorts utilised whole genome
 sequencing data aligned to the GRCh38 reference genome.

378

We pre-phased and imputed the microarray genotypes to the 1000 Genomes 30x on GRCh38 reference panel⁸³ using Eagle v2.4.1⁸⁸ and Minimac4⁸⁶. We used bcftools v1.9.0 to exclude variants with minor allele frequency (MAF) < 0.01 and imputation quality score R² < 0.4 from downstream analysis. The genotype imputation and quality control steps are implemented in <u>eQTL-Catalogue/genimpute</u> (v22.01.1) workflow available from GitHub. Subsequently, we used QCTOOL v2.2.0 to convert imputed genotypes from VCF format to bgen format for *trans*-eQTL analysis with regenie.

386 Gene expression data

Studies. We used gene expression data from seven RNA-seq studies (TwinsUK⁷⁵, CoLaus^{76,77},
 GEUVADIS⁷⁸, GENCORD⁸⁰, GTEx v8¹⁷, CAP⁸¹, MAGE³⁰) and three microarray studies
 (ALSPAC^{31,73,74}, MRCA⁷⁹ and MRCE⁷⁹).

390

391 **RNA-seq guantification and normalisation**. RNA-seq data were pre-processed as described 392 previously⁸⁹. Briefly, quantification of the RNA-seq data was performed using the eQTL-393 Catalogue/maseg workflow (v22.05.1) implemented in Nextflow. Before quantification, we used 394 Trim Galore v0.5.0 to remove sequencing adapters from the fastq files. For gene expression quantification, we used HISAT2⁹⁰ v2.2.1 to align reads to the GRCh38 reference genome 395 396 (Homo sapiens.GRCh38.dna.primary assembly.fa file downloaded from Ensembl). We counted the number of reads overlapping the genes in the GENCODE V30 reference transcriptome 397 398 annotations with featureCounts v1.6.4.

399

400 We excluded all samples that failed the quality control steps as described previously⁸⁹. We 401 normalised the gene counts using the conditional quantile normalisation (cgn) R package

- 402 v1.30.0 with gene GC nucleotide content as a covariate. We downloaded the gene GC content
- 403 estimates from Ensembl biomaRt and calculated the exon-level GC content using bedtools
- 404 v2.19.0⁹¹. We also excluded lowly expressed genes, where 95 per cent of the samples within a
- 405 dataset had transcripts per million (TPM)-normalised expression less than 1. Subsequently, we
- 406 used the inverse normal transformation to standardise quantification estimates. Normalisation
- 407 scripts together with containerised software are publicly available at https://github.com/eQTL-
- 408 <u>Catalogue/qcnorm</u>.
- 409

410 Microarray data processing. Gene expression from 877 individuals in the ALSPAC cohort was 411 profiled using Illumina Human HT-12 V3 BeadChips microarray. We used the normalised gene 412 expression matrix from the original publication³¹. In the MRCA cohort, gene expression from 327 413 individuals was profiled using the Human Genome U133 Plus 2.0 microarray. We downloaded

- 414 the raw CEL files from ArrayExpress (E-MTAB-1425) and normalised the data using the Robust
- 415 Multi-Array Average (RMA) method from the affy Bioconductor package⁹². In the MRCE cohort,

- 416 gene expression from 484 individuals was profiled using the Illumina Human-6 v1 Expression
- 417 BeadChip. As raw data was unavailable, we downloaded the processed gene expression matrix
- 418 from ArrayExpress (E-MTAB-1428). In all three microarray datasets, we applied inverse normal
- transformation to each probe before performing *trans*-eQTL analysis. If there were multiple
- 420 probes mapping to the same gene, the probe with the highest average expression was used.

421 *Trans*-eQTL mapping and meta-analysis

- 422 We performed independent quality control and normalisation on all datasets and only included
- 423 18,792 protein coding genes in the analysis. *Trans*-eQTL analysis was conducted separately on
- 424 each dataset with regenie⁹³. For studies containing related samples (TwinsUK, MRCA and
- 425 MRCE) and ALSPAC, both step 1 and step 2 commands were employed, while for other
- 426 datasets with a smaller number of unrelated samples (Table S1), regenie was run in the linear
- regression mode (step 2 only). We used sex and six principal components of the normalised
- 428 gene expression matrix and six principal components of genotype data as covariates in the
- 429 *trans*-eQTL analysis. All scripts used to run *trans*-eQTL are publicly available at
- 430 <u>https://github.com/freimannk/regenie_analysis</u>. Subsequently, we performed an inverse-
- 431 variance weighted meta-analysis across studies. Meta-analysis workflow is available at
- 432 <u>https://github.com/freimannk/regenie_metaanalyse</u>.
- 433
- 434 We used a *cis* window of ± 5Mb to assign identified eQTLs into *cis* and *trans* eQTLs. To
- determine significant loci, we excluded variants proximal (±1.5Mb) to the most highly associated
- 436 variant per gene. This approach allowed us to identify distinct and robust signals while
- 437 mitigating potential confounding effects from nearby variants. By applying these filters, we found
- 438 79 *trans*-eQTLs loci at a suggestive p-value threshold of 1×10^{-11} .
- 439 Accounting for cross-mappability
- 440 A major source of false positives in *trans*-eQTL analysis is cross-mappability, whereby RNA-seq
- 441 reads from gene A erroneously align to gene B, leading to very strong apparent *trans*-eQTL
- signals^{11,29}. To exclude potential cross-mappability artefacts, we excluded all *trans*-eQTLs
- 443 where there was high cross-mappability (cross-mappability score from Saha *et al*²⁹ > 1) between
- the *trans*-eQTL target gene and at least one protein coding gene in the *cis* region (±1.5Mb) of
- the *trans* eQTL lead variant. Since some of the strongest cross-mappability artefacts affected
- 446 one or few target genes (Table S3), we further restricted our analysis to *trans*-eQTL loci that
- had five or more target genes with $p < 5x10^{-8}$ and cross-mappability score < 1.

448 Replication of *trans*-eQTL associations

- 449 MAGE. Since we used somewhat arbitrary thresholds to define the initial set of 10 loci (lead p-
- 450 value < 1×10^{-11} , five or more targets with p < 5×10^{-8}), we sought to replicate our findings in an
- 451 independent Multi-ancestry Analysis of Gene Expression (MAGE)³⁰ cohort. MAGE consisted of
- data from 731 lymphoblastoid cell lines from the 1000 Genomes project, 682 of which also had
- 453 whole genome sequencing data available. We used two strategies to assess replication. First,
- 454 we assessed if the lead variant-gene pair was nominally significant (p < 0.05) in the replication

455 dataset with concordant direction of effect. Based on this criterion, 7/10 loci replicated (Table 456 S2). Secondly, since all of our loci had multiple target genes, we used the pi1 statistic to 457 estimate the proportion of FDR < 5% target gene at each locus that had a non-null p-value in 458 the replication dataset⁹⁴. We used the qvalue R package⁹⁵ to calculate pi1 = 1-qvalue(5% FDR 459 trans gene p-values)\$pi0. For 3/10 loci, the proportion of non-null p-values was > 0.5 (Table 460 S2). Note that replication in an independent cohort does not help to reduce false positives due

- to cross-mappability, as cross-mappability artefacts tend to be highly replicable²⁹.
- 462

463 eQTLGen Consortium. The eQTLGen Consortium is an initiative to investigate the genetic
 464 architecture of blood gene expression and to understand the genetic basis of complex traits. We
 465 used interim summary statistics from eQTLGen phase 2, wherein a genome-wide eQTL
 466 analysis has been performed in 52 cohorts, representing 43,301 individuals.

467

All 52 cohorts performed cohort-specific analyses as outlined in the eQTLGen analysis
cookbook (<u>https://eqtlgen.github.io/eqtlgen-web-site/eQTLGen-p2-cookbook.html</u>). Genotype
quality control was performed according to standard bioinformatics practices and included
quality metric-based variant and sample filtering, removing related samples, ethnic outliers and
population outliers. Genotype data was converted to genome build hg38 if not done so already
and the autosomes were imputed using the 1000 Genomes 30x on GRCh38 reference panel⁸³
(all ancestries) using the eQTLGen imputation pipeline (eQTLGen/eQTLGenImpute).

475

476 Like the genotype data, gene expression data was processed using the eQTLGen data QC 477 pipeline (eQTLGen/DataQC). For array-based datasets, we used the results from the empirical probe mapping approach from our previous study⁶ to connect the most suitable probe to each 478 479 gene which has previously been to show expression in the combined BIOS whole blood 480 expression dataset. Raw expression data was further normalized in accordance with the 481 expression platform used (quantile normalization for Illumina expression arrays and TMM⁹⁶ for 482 RNA-seq) and inverse normal transformation was performed. Gene expression outlier samples 483 were removed and gene summary information was collected for filtering at the central site. 484 Samples for whom there were mismatches in genetically inferred sex, reported sex, or the 485 expression of genes encoded from sex chromosomes were removed. Similarly, samples with 486 unclear sex, based on genetics or gene expression were removed.

487

An adaptation of the HASE framework⁹⁷ was used to perform genome-wide meta-analysis. For
 genome-wide eQTLs analysis, this limits the data transfer size while ensuring participant
 privacy. At each of the cohorts, the guality controlled and imputed data was processed and

490 privacy. At each of the conorts, the quality controlled and imputed data was processed and 491 encoded so that the individual level data can no longer be extracted, but while still allowing

- 492 effect sizes to be calculated for the linear relationship between variants and gene expression
 493 (eQTLGen/ConvertVcf2Hdf5 and eQTLGen/PerCohortDataPreparations).
- 494 Centrally, the meta-analysis pipeline was run on the 52 cohorts. The pipeline which performs
- 495 per cohort calculations of effect sizes and standard errors and the inverse variance meta-
- 496 analysis is available at <u>eQTLGen/MetaAnalysis</u>. We included 4 genetic principal components,
- 497 20 gene expression principal components and other technical covariates (e.g. RNA integrity
- 498 number) where available. Per every dataset, genes were included if the fraction of unique

- expression values was equal or greater than 0.8, Variants were included based on imputation guality, Hardy-Weinberg equilibrium (HWE) and minor allele frequency (MAF) (Mach $R2 \ge 0.4$,
- 500 quality, hardy-weinberg equilibrium (HWE) and minor arele frequency (MAF) (Mach $KZ \ge 0.3)$ 501 HWE p $\ge 1 \times 10^{-6}$ and MAF ≥ 0.01). In an additional step, genes were filtered to include only
- 502 those genes that were available in at least 50% of the cohorts and 50% of the samples.

503 Differential gene expression in SLE cases *versus* controls

We re-analysed the microarray gene expression data from Banchereau et al. 2016⁴² to explore differential gene expression between SLE cases and controls. After downloading the processed data from GEO (GSE65391), we selected one sample from each individual for our analysis based on their earliest recorded visits. The filtered dataset comprised a total of 204 samples, including 46 samples from healthy individuals and 158 samples from individuals diagnosed with

- 509 SLE. We also applied the inverse normal transformation to standardise the gene expression
- 510 values. Subsequently, we used the Python statsmodels⁹⁸ module to fit a linear model to identify
- 511 genes that were differentially expressed between SLE cases and controls. We included gender,
- 512 age and batch as covariates in all models.

513 Overlap between USP18 target genes and GWAS hits for SLE

- 514 We download the list of prioritised target genes for the Yin *et al* GWAS study (GCST011956)
- 515 from the Open Targets Genetics Portal. We combined the list of genes prioritised by either the
- 516 L2G or the closest gene approach, yielding n = 109 target genes. We then overlapped these
- 517 target lists with the list of 50 *trans*-eQTL targets for the *USP18* locus (FDR < 5%).

518 Single-cell differential gene expression in resting and stimulated B-cells

Sample collection, cell isolation and cryopreservation. Blood samples were collected from
five healthy Mexican individuals (three males and two females). Peripheral blood mononuclear
cells (PBMCs) were isolated using Vacutainer CPT tubes, according to manufacturer
instructions. Samples were cryopreserved in RPMI 1640 culture media (Sigma), Fetal Bovine
Serum (FBS) and Dimethyl sulfoxide (DMSO) and stored at -80°C for 24h, before being
transferred to liquid nitrogen.

525

Thawing and stimulation. Cryopreserved PBMCs were thawed quickly and washed in 14mL of room temperature complete RPMI 1640 media (10% FBS, 1% Penicillin-Streptomycin, 1% L-Glutamine). Cells were incubated at 37 \Box °C, 5% CO₂ for 2h. Cells were then stimulated with interferon alpha (IFN- \Box , Bio-techne) and R-848 (Resiquimod, Cambridge Bioscience) at a working concentration of 1000U/mL and 2µg/ml, respectively. Cells were incubated at 37 \Box °C, 5% CO2 and harvested after 16h, 40h and 64h of stimulation. Unstimulated cells were kept in culture without any stimuli for 16h (i.e., 0h of activation).

533

Multiplexing, CITE-seq staining & scRNA-seq. Upon harvesting, cells were resuspended in a
 cell staining buffer (Biolegend) and cell hashing and genotype-based multiplexing was
 performed. Donors of the same stimulation condition were mixed at equal ratios (each pool

537 corresponded to a mix of cells from four to five different individuals). These pools were stained

538 with the TotalSeq-C Human Universal Cocktail, V1.0 (137 cell surface proteins (CSP),

- 539 Biolegend), in addition to a unique hashtag antibody oligonucleotide (HTO, Biolegend) which
- 540 corresponds to the stimulation condition pool. After staining and washing, all stimuli condition
- 541 pools were pooled together at equal ratios. This pool was then stained with live/dead dye 4,6-
- 542 diamidino-2-phenylindole (DAPI, Biolegend) and dead cells were removed using fluorescence-543 activated cell sorting.
- 543 act 544
- 545 Cells were next processed using the 10X Genomics Immune Profiling 5' high-throughput (HT) 546 v2 kit, as specified by the manufacturer's instructions. 1.15×10^5 cells were loaded into each inlet 547 of a 10X Chromium X to create Gel Bead-in-emulsions (GEMs). Two 10X HT reactions were 548 loaded per time point of sample processing (targeted recovery was 40,000 cells per 10X 549 reaction). Reverse transcription was performed on the emulsion, after which cDNA and CITEseq 550 supernatant were purified, amplified and used to construct RNA-sequencing and CSP 551 sequencing libraries, respectively. These RNA and CSP libraries were sequenced at a 5:1 ratio, 552 respectively, using the Illumina NoveSeg 6000 S4, with 100-bp paired-end reads and all 10X 553 reactions were mixed at equal ratios and sequenced across two lanes.
- 554

555 Deconvolution of single cells by genotype. Each 10X reaction comprised a mix of cells from 556 unrelated individuals. Thus, natural genetic variation was used to assign cells to their respective 557 individuals. First, a list of common exonic variants was compiled from the 1000 Genomes 558 Project phase 3 exome-sequencing data (MAF> 0.05). Next, cellSNP (v1.2.1) was used to 559 generate pileups at the genomic location of these variants. These pileups, in combination with 560 the variants called from genotyping in each individual, were used as an input for Vireo⁹⁹ (v0.5.7). 561 If any cell had less than 0.9 posterior probability of belonging to any individual or were of mixed 562 genotypes they were labelled as 'unassigned' and 'doublets', respectively, and removed from 563 downstream analysis.

564

Data processing and quality controls. Raw scRNA-seg and CITE-seg data were processed 565 566 using the Cell Ranger Multi pipeline (v7.0.0, 10x Genomics). In brief, RNA and CSP library 567 reads were first assigned to cells. RNA reads were then aligned to the GRCh38 human 568 reference genome and CSP antibody reads were matched to the provided list of known 569 barcodes. Ensembl version 93 was used as a reference for gene annotation, and gene 570 expression was quantified using reads assigned to cells and confidently mapped to the genome. 571 Additionally, Cell Ranger multi was used to deconvolute samples based on HTOs. It uses an 572 algorithm which employs a latent variable model over a state space composed of each HTO

- 573 used in the experiment to assign each cell to a stimulation condition or as a doublet.
- 574

Results from RNA and CSP quantification in Cell Ranger were imported into RStudio (v4.3.1)
and analysed using Seurat (v5.0.1). Any cell identified as doublet or unassigned by Vireo and or
antibody hashtag deconvolution method were excluded. 10X reactions were split by time point
and stimuli condition. Cells with 1.5 - 2.5 median absolute deviations below the median of genes
and counts detected were discarded. Additionally, cells with 3 - 4 median absolute deviation
above the median for the percentage of mitochondrial reads detected were discarded. The

resulting cells were then annotated by Azimuth¹⁰⁰ (v0.5.0), using the Azimuth PBMC reference dataset that was generated as part of the Hao and Hao *et al*, 2021 paper¹⁰⁰.

583

584 Pseudobulk and normalisation. Raw counts were pseudobulked by Azimuth annotated level 1
 585 cell types (CD4, CD8, B, Mono, DC, NK, Other and Other T) per donor, per time point and per
 586 stimulation condition, via edgeR¹⁰¹ (v4.0.16). Pseudobulked raw counts were then counts per
 587 million (CPM) normalised and log₂ transformed with edgeR.

588

589 Data availability

590 The whole genome sequencing data for the GEUVADIS and MAGE studies was downloaded

591 from the 1000 Genomes <u>website</u>. The GEUVADIS RNA-seq data was downloaded from the

592 European Nucleotide Archive (ENA) under accession <u>PRJEB3366</u>. The MAGE RNA-seq data 593 was downloaded from the ENA (accession <u>PRJNA851328</u>). The genotype and RNA-seq data

594 from the GENCORD study was downloaded from European Genotype-phenotype Archive

595 (EGA) under accessions EGAD00001000425 and EGAD00001000428. The microarray gene

596 expression data from the MRCA and MRCE studies was downloaded from ArrayExpress (E-

597 <u>MTAB-1425</u> and <u>E-MTAB-1428</u>) and the genotype data was downloaded from EGA

598 (EGAS0000000137). The gene expression and genotype data from GTEx and CAP studies

599 was downloaded from dbGaP (accessions <u>phs000424.v8.p2</u> and <u>phs000481.v3.p2</u>). The RNA-

600 seq data from the TwinsUK study was downloaded from EGA (EGAD00001001086) and

601 genotype data was obtained from TwinsUK (https://twinsuk.ac.uk/resources-for-

602 <u>researchers/access-our-data/</u>). The informed consent obtained from ALSPAC participants does

not allow the microarray and genotype data to be made freely available through any third party

604 maintained public repository. However, data used for this study can be made available on

605 request to the ALSPAC Executive. The ALSPAC data management plan describes in detail the

policy regarding data sharing, which is through a system of managed open access. Fullinstructions for applying for data access can be found here:

608 <u>http://www.bristol.ac.uk/alspac/researchers/access/</u>. The ALSPAC study website contains

609 details of all the data that are available (<u>http://www.bristol.ac.uk/alspac/researchers/our-data/</u>).

610 The RNA-seq and genotype data from the CoLaus cohort can be accessed by directly

611 contacting the cohort (<u>https://www.colaus-psycolaus.ch/professionals/how-to-collaborate/</u>). The

612 MetaLCL full *trans*-eQTL meta-analysis summary statistics are available from the eQTL

613 Catalogue FTP server (<u>https://www.ebi.ac.uk/eqtl/Data_access/</u>) and additional documentation

614 is available on the project website (<u>https://github.com/AlasooLab/MetaLCL</u>).

615 URLs

- 616 MetaLCL website: <u>https://github.com/AlasooLab/MetaLCL</u>
- 617 MetaLCL trans-eQTL analysis workflow: <u>https://github.com/freimannk/regenie_analysis</u>
- 618 MetaLCL meta-analysis workflow: <u>https://github.com/freimannk/regenie_metaanalyse</u>
- 619 eQTL Catalogue website: <u>https://www.ebi.ac.uk/eqtl/Data_access/</u>
- 620 eQTL Catalogue genotype imputation workflow: <u>https://github.com/eQTL-Catalogue/genimpute</u>

- 621 eQTL Catalogue RNA-seq processing workflow: <u>https://github.com/eQTL-Catalogue/rnaseq</u>
- 622 eQTL Catalogue data normalisation workflow: <u>https://github.com/eQTL-Catalogue/qcnorm</u>
- 623 eQTLGen analysis cookbook: <u>https://eqtlgen.github.io/eqtlgen-web-site/eQTLGen-p2-</u>
- 624 <u>cookbook.html</u>
- 625 eQTLGen data QC workflow: <u>https://github.com/eQTLGen/DataQC</u>
- 626 eQTLGen genotype conversion workflow: <u>https://github.com/eQTLGen/ConvertVcf2Hdf5</u>
- 627 eQTLGen per-cohort analysis workflow:
- 628 <u>https://github.com/eQTLGen/PerCohortDataPreparations</u>
- 629 eQTLGen meta-analysis workflow: <u>https://github.com/eQTLGen/MetaAnalysis</u>
- 630 eQTLGen genotype imputation workflow: <u>https://github.com/eQTLGen/eQTLGenImpute</u>
- 631 QCTOOL: <u>https://www.chg.ox.ac.uk/~gav/qctool_v2/</u>

632 Declaration of interests

633 The authors declare no competing interests.

634 Acknowledgements

- 635 Most of the analysis presented in the paper were performed at the High Performance
- 636 Computing Center, University of Tartu. We are extremely grateful to all the families who took
- 637 part in the ALSPAC study, the midwives for their help in recruiting them, and the whole ALSPAC
- team, which includes interviewers, computer and laboratory technicians, clerical workers,
- 639 research scientists, volunteers, managers, receptionists and nurses. This work received support
- 640 from Christian Molina-Aguilar, Carina Uribe Díaz, and Alejandra Castillo Carbajal. We thank the
- FACS facility and sequencing pipelines at Wellcome Sanger Institute for their assistance in data
- 642 generation, and the Human Genetics Informatics for their support in sequence data processing.
- We thank Bess L. Chau for assistance in the experiments involving generation of single-cell
 RNAseq data from stimulated PBMCs. We thank Karatug Ozan Bircan, Abayomi Mosaku, Laura
- 645 Harris and Helen Parkinson for assistance with hosting the full *trans*-eQTL summary statistics
- 646 on the eQTL Catalogue FTP server.

647 Funding

648 K.F and L.S. were supported by a grant from Open Targets (grant no. OTAR2069). K.A was

- 649 supported by the Estonian Research Council (grant no. PSG415). K.A. also received funding
- from the European Union's Horizon 2020 research and innovation program (grant no. 825775).
- 651 GT, CPJ and TSR were supported by Open Targets (grant no. OTAR2064) and the Wellcome
- 652 Grant (ref. 220540/Z/20/A, 'Wellcome Sanger Institute Quinquennial Review 2021-2026). SB
- was supported by the Swiss National Science Foundation (grant no. 310030_152724/1). K.K.
- 654 was supported by the Estonian Research Council (grant no. PRG1117). AMR was supported by
- 655 CONACYT-FORDECYT-PRONACES grant no. [11311] and Programa de Apoyo a Proyectos
- 656 de Investigación e Innovación Tecnológica–Universidad Nacional Autónoma de México
- 657 (PAPIIT-UNAM) IN218023. ALHL is a doctoral student from Programa de Doctorado en
- 658 Ciencias Biomédicas, Universidad Nacional Autónoma de México (UNAM), and she receives

- 659 fellowship 790972 from Consejo Nacional de Humanidades, Ciencias y Tecnologías
- 660 CONAHCYT, México. The UK Medical Research Council and Wellcome (Grant ref:
- 661 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. ALSPAC GWAS
- data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute
- and LabCorp (Laboratory Corporation of America) using support from 23andMe. This
- 664 publication is the work of the authors and they will serve as guarantors for the contents of this
- 665 paper.

666 Author contributions

- 667 K.F. performed *trans*-eQTL analysis on nine cohorts and also performed the meta-analysis
- 668 across cohorts. A.B. performed *trans*-eQTL analysis on the CoLaus cohort. K.F., J.C., E.R.H.,
- J.C.M., N.N., H.O., L.S., M.C.T., G.T., K.K. and K.A. interpreted the results and prioritised
- 670 follow-up analyses. T.S.R. generated and analysed single-cell RNAseq data under C.P.J. and
- 671 G.T. supervision. A.L.H.-L. collected blood samples for single-cell RNAseq under A.M.-R.
- 672 supervision. R.W. performed replications in the eQTLGen Consortium under U.V. and L.F.
- 673 supervision. S.B. and K.A. supervised the research. K.F. and K.A. wrote the manuscript with
- 674 feedback from all authors.

675 Supplementary Information

- 676
- 677 1. eQTLGen Consortium Author information
- 678 2. Supplementary Note
- 679 3. Table S1
- 680 4. Figure S1-S9

eQTLGen Consortium – Author information

683

684 Author list is ordered alphabetically.

685

Habibul Ahsan¹, Marta E. Alarcón-Riquelme^{2,3}, Philip Awadalla⁴, Guillermo Barturen^{5,6,2}, Alexis Battle⁷, 686 Frank Beutner⁸, Cornelis Blauwendraat^{9,10}, Collins Boahen^{11,12}, Toni Boltz¹³, Dorret I. Boomsma^{14,15,16}, 687 Andrew Brown¹⁷, John Budde^{18,19}, Katie L. Burnham²⁰, John Chambers^{21,22,23}, Evans Cheruiyot²⁴, Surya 688 B. Chhetri²⁵, Annique Claringbould^{26,27}, PRECISESADS Clinical Consortium², DIRECT Consortium²⁸, 689 Carlos Cruchaga^{18,29,30,31,32,33}, Kensuke Daida^{9,10,34}, Emma E. Davenport²⁰, Devin Dikec^{18,19}, Théo 690 Dupuis¹⁷, Diptavo Dutta³⁵, Tõnu Esko³⁶, Radi Farhad³⁷, Aiman Farzeen^{38,39}, Marie-Julie Favé⁴⁰, Lude Franke^{26,41}, Tim Frayling⁴², Koichi Fukunaga⁴³, J. Raphael Gibbs⁴⁴, Greg Gibson⁴⁵, Priyanka Gorijala^{18,19}, 691 692 Binisha Hamal Mishra^{46,47,48}, Takanori Hasegawa⁴⁹, Michael Inouye^{50,51,52,53,54,55}, Farzana Jasmine¹, Matt 693 Johnson^{18,19}, Muhammad G. Kibriya¹, Holger Kirsten^{56,57}, Julian C. Knight⁵⁸, Peter Kovacs^{59,60}, Knut 694 Krohn⁶¹, Viktorija Kukushkina³⁶, Vinod Kumar^{11,12,62,63}, Mika Kähönen^{47,64}, Sandra Lapinska⁶⁵, Terho 695 Lehtimäki^{46,47,48}, Yun Li^{66,67,68}, Markus Loeffler^{69,70}, Marie Loh^{21,71,72,23}, Leo-Pekka Lyytikäinen^{46,47,48}, Javier Martin⁷³, Angel Martinez-Perez⁷⁴, Allan McRae²⁴, Lili Milani³⁶, Pashupati P. Mishra^{46,47,48}, Younes 696 697 Mokrab³⁷, Grant Montgomery²⁴, Juha Mykkänen^{75,76}, Reedik Mägi³⁶, Martina Müller-Nurasyid⁷⁷, Haroon 698 Naeem³⁷, Sini Nagpal⁴⁵, Ho Namkoong⁷⁸, Matthias Nauck⁷⁹, Yukinori Okada^{80,81,82,83,84}, Roel Ophoff^{65,13,85}, Katja Pahkala^{76,75,86}, Bogdan Pasaniuc^{65,87,13,88}, Dirk S. Paul^{50,51,89}, Elodie Persyn^{50,51,90}, Brandon Pierce¹, 699 700 René Pool^{91,15}, Holger Prokisch^{92,93}, Laura Raffield⁶⁷, Venket Raghavan⁶⁹, Olli Raitakari^{94,95,75,96}, Emma 701 Raitoharju^{97,98}, Jansen Rick^{15,99}, María Rivas-Torrubia², Ruth D. Rodríguez², Suvi P. Rovio^{76,75}, Jessie 702 Sanford^{18,19}, Markus Scholz^{69,70}, Eline Slagboom¹⁰⁰, José Manuel Soria⁷⁴, Juan Carlos Souto⁷⁴, Michael Stumvoll^{101,102,103}, Yun Ju Sung^{18,19}, Darwin Tay²¹, Alexander Teumer^{104,105}, Joachim Thiery^{70,106}, Alex Tokolyi²⁰, Lin Tong¹, Anke Tönjes¹⁰¹, Jan Veldink¹⁰⁷, Joost Verlouw¹⁰⁸, Peter M. Visscher²⁴, Ana Viñuela¹⁰⁹, Urmo Võsa³⁶, Uwe Völker^{110,111}, Qingbo S. Wang^{80,81,82}, Robert Warmerdam^{26,41}, Stefan 703 704 705 706 Weiss^{112,113}, Jia Wen⁶⁷, Harm-Jan Westra^{26,41}, Andrew Wood⁴², Manke Xie⁴⁵, Dasha Zhernakova²⁶, 707 Marleen van Greevenbroek¹¹⁴, Joyce van Meurs^{115,116} 708

- 709
- 710 1. Department of Public Health Sciences, University of Chicago, Illinois, USA

2. Pfizer–University of Granada–Junta de Andalucía Centre for Genomics and Oncological Research,

- 712 Granada, Spain
- 3. Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
- 4. Ontario Institute for Cancer Research, University of Toronto
- 5. Department of Genetics, Faculty of Science, University of Granada, 18071 Granada, Spain
- 716 6. Bioinformatics Laboratory, Biotechnology Institute, Centro de Investigación Biomédica, PTS, Avda. del
- 717 Conocimiento s/n, 18100 Granada, Spain
- 718 7. Department of Biomedical Engineering, Department of Computer Science, Department of Genetic
- 719 Medicine, Johns Hopkins University, Baltimore, MD, USA
- 8. Department of Internal Medicine/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig,Germany
- 9. Integrative Neurogenomics Unit, Laboratory of Neurogenetics, National Institute on Aging, National
- 723 Institutes of Health, Bethesda, MD, USA
- 10. Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National
- 725 Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
- 11. Department of Internal Medicine and Radboud Institute of Molecular Life Sciences (RIMLS), Radboud
- 727 University Medical Center, Nijmegen, 6525 HP, the Netherlands

- 12. Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud
- 729 University Medical Center, Nijmegen, 6525 HP, the Netherlands
- 13. Department of Human Genetics, David Geffen School of Medicine, University of California Los
- 731 Angeles, Los Angeles, CA, USA
- 732 14. Amsterdam Reproduction & Development (AR&D) research institute, Amsterdam, the Netherlands
- 733 15. Amsterdam Public Health research institute, Amsterdam, the Netherlands
- 16. Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research,
- 735 Amsterdam, Vrije Universiteit Amsterdam
- 736 17. Population Health and Genomics, University of Dundee, Dundee, Scotland, UK.
- 737 18. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States
- 738 19. NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO739 63110. USA
- 740 20. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK
- 741 21. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
- 742 22. Precision Health Research (PRECISE), Singapore
- 743 23. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London,
- 744 United Kingdom
- 745 24. Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia
- 746 25. Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA
- 747 26. Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen,
- 748 The Netherlands
- 749 27. Department of Internal Medicine, Erasmus MC, Erasmus University Medical Center Rotterdam,
- 750 Rotterdam, The Netherlands
- 751 28. https://directdiabetes.org/
- 752 29. NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO
- 753 63110, USA
- 754 30. Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA
- 755 31. Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis,
- 756 MO, United States
- 757 32. Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO,
- 758 United States
- 759 33. Dominantly Inherited Alzheimer Disease Network (DIAN)
- 760 34. Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan
- 761 35. Division of Cancer Epidemiology & Genetics, National Cancer Insititute, Bethesda, MD, USA
- 762 36. Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
- 763 37. Human Genetics Department, Sidra Medicine, Doha, Qatar
- 764 38. Institute of Human Genetics, School of Medicine, Technische Universität München, Munich, Germany
- 765 39. Institute of Neurogenomics, Computational Health Center, Helmholtz Zentrum München, Munich,
- 766 Germany.
- 767 40. Ontario Institute for Cancer Research
- 768 41. Oncode Institute, Groningen, The Netherlands
- 769 42. Genetics of Complex Traits, University of Exeter Medical School, Exeter, UK
- 43. Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo,Japan.
- 44. Computational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, Bethesda,MD, USA
- 45. Center for Integrative Genomics, Georgia Institute of Technology, Atlanta, GA, USA.
- 46. Department of Clinical Chemistry, Faculty of Medicine and Health Technology, Tampere University,
- 776 Tampere, Finland

- 777 47. Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology,
- 778 Tampere University, Tampere, Finland
- 779 48. Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland
- 780 49. M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
- 781 50. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary
- 782 Care, University of Cambridge, Cambridge, UK
- 783 51. Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK
- 784 52. Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care,
- 785 University of Cambridge, Cambridge, UK
- 786 53. Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, VIC, 787 Australia
- 788 54. Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, 789 Cambridge, UK
- 790 55. British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK.
- 791 56. LIFE – Leipzig Research Center for Civilization Diseases, Leipzig University, Germany
- 792 57. Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Germany
- 793 58. Centre for Human Genetics, University of Oxford, Oxford, UK
- 794 59. Integrated Research and Treatment Center (IFB) Adiposity Diseases, University of Leipzig, D-04103 795 Leipzig, Germany
- 796 60. Department of Medicine, University of Leipzig, D-04103 Leipzig, Germany
- 797 61. Medical Faculty, University of Leipzig, Leipzig, Germany.
- 798 62. Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen,
- 799 9700 RB, the Netherlands
- 800 63. Nitte (Deemed to Be University), Medical Sciences Complex, Nitte University Centre for Science
- 801 Education and Research (NUCSER), Deralakatte, Mangalore, 575018, India
- 802 64. Department of Clinical Physiology, Tampere University Hospital, Tampere Finland
- 803 65. Bioinformatics Interdepartmental Program, University of California Los Angeles, Los Angeles, CA, 804 USA
- 805 66. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 806 67. Department of Genetics, University of North Carolina, Chapel Hill, NC, USA
- 807 68. Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 808 69. Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany
- 809 70. Leipzig Research Centre for Civilization Diseases, Leipzig University, Leipzig, Germany
- 810 71. National Skin Centre, Research Division, Singapore
- 811 72. Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore
- 812 73. Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones
- 813 Científicas (IPBLN-CSIC), Granada, Spain
- 814 74. Unit of Genomic of Complex Diseases, Institut de Recerca Sant Pau (IR Sant Pau), Barcelona, Spain.
- 815 75. Centre for Population Health Research, University of Turku and Turku University Hospital, Turku,
- 816 Finland
- 817 76. Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, 818
- Finland
- 819 77. Institute for Medical Biometry, Epidemiology and Informatics (IMBEI), Mainz, Germany
- 820 78. Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
- 821 79. Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, 822 Germany
- 823 80. Department of Genome Informatics, Graduate School of Medicine, the University of Tokyo, Tokyo,
- 824 Japan
- 825 81. Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan

- 826 82. Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
- 827 83. Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka
 828 University, Suita, Japan
- 829 84. Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), Osaka University, Suita,830 Japan.
- 831 85. Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, David
- 832 Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA
- 833 86. Paavo Nurmi Centre, Unit of Health and Physical Activity, University of Turku, Turku, Finland
- 87. Department of Computational Medicine, David Geffen School of Medicine, University of California Los
 Angeles, Los Angeles, CA, USA
- 836 88. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of
 837 California Los Angeles, Los Angeles, CA, USA
- 838 89. Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca,
 839 Cambridge, UK.
- 840 90. Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care,
- 841 University of Cambridge, UK.
- 842 91. Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- 843 92. Institute of Neurogenomics, Computational Health Center, Helmholtz Zentrum München, Neuherberg,844 Germany
- 845 93. School of Medicine, Institute of Human Genetics, Technical University of Munich, Munich, Germany
- 846 94. Research centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku,847 Finland
- 848 95. Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland
- 849 96. InFLAMES Research Flagship, University of Turku, Turku, Finland
- 850 97. Molecular Epidemiology, Faculty of Medicine and Health Technology, Tampere University, Tampere,851 Finland
- 852 98. Tampere University Hospital, Tampere, Finland
- 853 99. Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Psychiatry & Amsterdam
- 854 Neuroscience -Complex Trait Genetics (VUmc) and Mood, Anxiety, Psychosis, Stress & Sleep
- 855 100. Section of Molecular Epidemiology, Department of Biomedical Data Sciences, Leiden University
- 856 Medical Center, Leiden, the Netherlands
- 857 101. Medical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical
 858 Center, Leipzig, Germany
- 859 102. Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG), Helmholtz Zentrum
- 860 München, University of Leipzig and University Hospital Leipzig, Leipzig, Germany
- 861 103. Deutsches Zentrum für Diabetesforschung, Neuherberg, Germany
- 862 104. Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
- 863 105. DZHK (German Center for Cardiovascular Research), partner site Greifswald, Greifswald, Germany
- 106. Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig
 Medical Center, Leipzig, Germany
- 866 107. Department of Neurology, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands
- 867 108. Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
- 868 109. Biosciences Institute, Faculty of Medical Sciences, University of Newcastle, Newcastle upon Tyne,
 869 UK
- 870 110. German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, D-17475 Greifswald,
 871 Germany
- 872 111. Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Felix-
- 873 Hausdorff-Strasse 8, D-17475 Greifswald, Germany

- 874 112. Interfaculty Institute of Genetics and Functional Genomics, University Medicine Greifswald,
- 875 Greifswald, 17475, Germany
- 876 113. German Center for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, 17475,
- 877 Germany.
- 878 114. CARIM, Maastricht University
- 879 115. Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The
- 880 Netherlands
- 116. Department of Orthopaedics and Sportsmedicine, Erasmus MC University Medical Center,
- 882 Rotterdam, The Netherlands.

884 Supplementary Note

885 MYBL2 regulates the expression of many cell cycle genes

886 At the MYBL2 locus, the lead variant chr20 43721344 C T was associated with the expression of 151 target genes at FDR 5% (Figure S8). The target genes were strongly enriched for the 887 Gene Ontology mitotic cell cycle term (GO:0000278, $p=2.607 \times 10^{-51}$) and the Reactome mitotic 888 cell cycle pathway (R-HSA-69278, p=1.216 \times 10⁻³⁵). Interestingly, 125/151 genes (82%) had 889 890 lower expression in carriers of the alternative T allele (Figure S8). The T allele of chr20 43721344 C T was also strongly associated ($p = 8.83 \times 10^{-218}$) with the decreased 891 expression of the MYBL2 transcription factor gene in cis (Figure S8). Since both the MYBL2 892 893 transcription factor located in *cis* and majority of the *trans*-genes had lower expression in the 894 carriers of the T allele, we hypothesised that MYBL2 might directly regulate these target genes. 895 To test this, we download ChIP-seg data for the MYBL2 transcription factor in the human K562 896 myelogenous leukemia cell line from the ENCODE project (ENCSR162IEM). We then asked 897 how many of the up- and downregulated genes had a MYBL2 ChIP-seq peak within +/- 2kb 898 from the annotated promoter of the gene. We found that 99/125 (78.4%) downregulated genes 899 had a MYBL2 peak in their promoter region (Figure S9). In contrast, only 1/26 upregulated 900 genes had a MYBL2 peak in their promoter region. As a negative control, we looked at the 404 901 5% FDR target genes of the SP140 locus (Table S2) and found that only 23/404 (5.6%) of the 902 target genes had a MYBL2 peak in their promoter region (Figure S9). 903

To further understand which cell cycle stage these *MYBL2* target genes might be involved in, we obtained the list of genes specific to G2M and S phases of the cell cycle from Tirosh et al. 2015^{102} using Seurat R package¹⁰³. We found that 33/125 genes downregulated by the *trans*eQTL variant were markers of the G2M phase which was significantly more than expected (p = 1.23×10^{-53}). In contrast, only 1/125 downregulated genes overlapped with markers of the S phase (p = 0.36). Of note, 2/26 upregulated genes overlapped S-phase markers (p = 0.004) and none of the upregulated genes overlapped G2M-phase markers.

911

912 Altogether, this evidence strongly suggests that MYBL2 directly regulates the expression of

913 G2M genes in *trans* by binding to their promoter sequences and is directly involved in the

- 914 regulation of the expression of these target genes.
- 915

916 **Table S1**. **Overview of the LCL eQTL discovery cohorts.** The cohorts included in the analysis

917 used a mixture of RNA-seq and microarray technologies and three cohorts (TwinsUK, MRCE

918 and MRCA) contained related samples.

Cohort	Sample size	Expression data	Genotype data	Relatedness
ALSPAC ^{31,73,74}	877	microarray	imputed (1000G 30x on GRCh38)	unrelated
TwinsUK ⁷⁵	735	RNA-seq	imputed (1000G 30x on GRCh38)	twins
CoLaus ^{76,77}	553	RNA-seq	imputed (TOPMed)	unrelated
GEUVADIS ⁷⁸	358	RNA-seq	WGS (1000G 30x on GRCh38)	unrelated
Liang_2013 (MRCE) ⁷⁹	484	microarray	imputed (1000G 30x on GRCh38)	siblings
Liang_2013 (MRCA) ⁷⁹	327	microarray	imputed (1000G 30x on GRCh38)	siblings
GENCORD ⁸⁰	187	RNA-seq	imputed (1000G 30x on GRCh38)	unrelated
GTEx ¹⁷	113	RNA-seq	WGS (GRCh38)	unrelated
CAP ⁸¹	100	RNA-seq	imputed (1000G 30x on GRCh38)	unrelated
MAGE ³⁰ (replication)	682	RNA-seq	WGS (GRCh38)	unrelated, diverse ancestries





Figure S1. Overview of *trans*-eQTL analysis at the relaxed $p < 5x10 \square \square$ threshold. The upper scatter plot shows the number of trans associations detected at each trans-eQTL locus with p-values < 5x10 \Box . Six largest *trans*-eQTL loci have been labelled with the name of the closest cis gene. The lower scatter plot shows all significant loci for each tested gene at the p < r5x10 \cong threshold. Cis associations are located on the diagonal while putative trans associations are located off diagonal.



932

933 Figure S2. Forest plots showing cohort-specific effect size for the four *trans-*eQTL loci

that replicated in the MAGE cohort. The points represent the *trans*-eQTL effect size estimates

935 from regenie and the error bars represent 95% confidence intervals.



- 936
- 937
- 938
- 939 Figure S3. Forest plots showing cohort-specific effect size for the remaining trans-eQTL
- 940 loci that either did not replicate in the MAGE cohort or corresponded to likely cross-
- 941 mappability artefacts (SENP7, ZNF781 and ZBTB10 loci). The points represent the trans-
- 942 eQTL effect size estimates from regenie and the error bars represent 95% confidence intervals.





944 Figure S4. Original regional association plot for the USP18 SLE GWAS locus from Yin et

945 *al.* 2020 study (top panel) and the summary statistics imputed with POEMColoc for the
 946 same locus (bottom panel).



948

949 Figure S5. Category III: other interferon alpha/beta signalling pathway genes that do not

950 belong to categories I or II (shown in Figure 3). The increased gene expression is marked in

951 red, while reduced gene expression is marked in blue. The visualisation illustrates the effect on

952 USP18 targets in relation to the risk allele. DE - differential gene expression in SLE cases

953 versus controls⁴²; GWAS - GWAS hits for SLE³³, ChEMBL, phase III - SLE phase III clinical

954 trials from ChEMBL⁵⁰, PID - genes causing primary immunodeficiency from Genomics England.



955

Figure S6. Fine-mapped splicing QTL (sQTL) in the OAS1 gene. (A) RNA-seq read
coverage of the OAS1 gene in the GEUVADIS LCL dataset, stratified by the genotype of the
fine-mapped sQTL variant chr12_112919388_G_A (posterior inclusion probability = 1). (B)
Exon-level effect sizes for the sQTL lead variant. (C) Boxplot of the absolute expression of the
short last intron of the OAS1 gene (highlighted on panel A) stratified by the genotype of the lead
sQTL variant. Interactive version of the plot can be viewed here.



965 Figure S7. Expression level of USP18 in resting and stimulated B-cell subset of

966 peripheral blood mononuclear cells (PBMCs). PBMCs were isolated from healthy donors and

967 stimulated with interferon-alpha (IFNa) or R848 for 16, 40 and 64 hours.

963



973 5%)





976

Figure S9. Overlap between *trans*-eQTL target genes and MYBL2 ChIP-seq peaks. The top
panel shows the proportion of the *MYBL2 trans*-eQTL target genes upregulated (left) or
downregulated (right) by the effect allele that contain a MYBL2 ChIP-seq peak within +/- 2kb
from the annotated promoter. The bottom panel shows the proportion of the *SP140 trans*-eQTL
target genes upregulated (left) or downregulated (right) by the effect allele that contain a MYBL2
ChIP-seq peak within +/- 2kb from the annotated promoter. Only genes downregulated by the
MYBL2 effect allele show a sizable overlap with MYBL2 ChIP-seq peaks.

985 References

- Aguet, F. *et al.* Molecular quantitative trait loci. *Nature Reviews Methods Primers* 3, 1–22
 (2023).
- Bauer, D. E. *et al.* An erythroid enhancer of BCL11A subject to genetic variation determines
 fetal hemoglobin level. *Science* 342, 253–257 (2013).
- 990 3. Frangoul, H. *et al.* CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
 991 *N. Engl. J. Med.* 384, 252–260 (2021).
- 4. Liu, X., Li, Y. I. & Pritchard, J. K. Trans Effects on Gene Expression Can Drive Omnigenic
 Inheritance. *Cell* **177**, 1022–1034.e6 (2019).
- Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK
 Biobank. *Nature* 1–10 (2023).
- 996 6. Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci
 997 and polygenic scores that regulate blood gene expression. *Nat. Genet.* 53, 1300–1310
- 998 (2021).
- 999 7. Westra, H.-J. *et al.* Systematic identification of trans eQTLs as putative drivers of known
 1000 disease associations. *Nat. Genet.* 45, 1238–1243 (2013).
- 1001 8. Ferkingstad, E. *et al.* Large-scale integration of the plasma proteome with genetics and
 1002 disease. *Nat. Genet.* 53, 1712–1721 (2021).
- 1003 9. Sun, B. B. et al. Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
- 10. Pietzner, M. *et al.* Mapping the proteo-genomic convergence of human diseases. *Science*374, eabj1541 (2021).
- 1006 11. Bonder, M. J. *et al.* Identification of rare and common regulatory variants in pluripotent cells
 using population-scale transcriptomics. *Nat. Genet.* **53**, 313–321 (2021).
- 1008 12. Kolberg, L., Kerimov, N., Peterson, H. & Alasoo, K. Co-expression analysis reveals
- 1009 interpretable gene modules controlled by trans-acting genetic variants. *Elife* **9**, e58705

- 1010 (2020).
- 1011 13. Kasela, S. et al. Pathogenic implications for autoimmune mechanisms derived by
- 1012 comparative eQTL analysis of CD4+ versus CD8+ T cells. *PLoS Genet.* **13**, e1006643
- 1013 (2017).
- 1014 14. Fairfax, B. P. *et al.* Innate immune activity conditions the effect of regulatory variants upon
 1015 monocyte gene expression. *Science* 343, 1246949 (2014).
- 1016 15. Brandt, M. *et al.* An autoimmune disease risk variant: A trans master regulatory effect
- 1017 mediated by IRF1 under immune stimulation? *PLoS Genet.* **17**, e1009684 (2021).
- 1018 16. Small, K. S. *et al.* Identification of an imprinted master trans regulator at the KLF14 locus
- related to multiple metabolic phenotypes. *Nat. Genet.* **43**, 561–564 (2011).
- 1020 17. Consortium, T. G. *et al.* The GTEx Consortium atlas of genetic regulatory effects across
 1021 human tissues. *Science* 369, 1318–1330 (2020).
- 1022 18. Yazar, S. *et al.* Single-cell eQTL mapping identifies cell type-specific genetic control of
 1023 autoimmune disease. *Science* 376, eabf3041 (2022).
- 1024 19. Small, K. S. *et al.* Regulatory variants at KLF14 influence type 2 diabetes risk via a female-
- specific effect on adipocyte size and body composition. *Nat. Genet.* **50**, 572–580 (2018).
- 1026 20. Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in Humans.
- 1027 *N. Engl. J. Med.* **373**, 895–907 (2015).
- 1028 21. Smemo, S. *et al.* Obesity-associated variants within FTO form long-range functional
 1029 connections with IRX3. *Nature* **507**, 371–375 (2014).
- 1030 22. Young, L. S. & Rickinson, A. B. Epstein-Barr virus: 40 years on. *Nat. Rev. Cancer* 4, 757–
 1031 768 (2004).
- 1032 23. Bjornevik, K. *et al.* Longitudinal analysis reveals high prevalence of Epstein-Barr virus
 1033 associated with multiple sclerosis. *Science* **375**, 296–301 (2022).
- 1034 24. Bar-Or, A. et al. Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging
- 1035 Immunotherapies. *Trends Mol. Med.* **26**, 296–310 (2020).

- 1036 25. James, J. A. et al. An increased prevalence of Epstein-Barr virus infection in young patients
- suggests a possible etiology for systemic lupus erythematosus. *J. Clin. Invest.* **100**, 3019–
 3026 (1997).
- 1039 26. Harley, J. B. *et al.* Transcription factors operate across disease loci, with EBNA2 implicated 1040 in autoimmunity. *Nat. Genet.* **50**, 699–707 (2018).
- 1041 27. Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and
- 1042 GlialCAM. *Nature* **603**, 321–327 (2022).
- 1043 28. Thomas, O. G. et al. Heightened Epstein-Barr virus immunity and potential cross-
- 1044 reactivities in multiple sclerosis. *PLoS Pathog.* **20**, e1012177 (2024).
- 1045 29. Saha, A. & Battle, A. False positives in trans-eQTL and co-expression analyses arising
- 1046 from RNA-sequencing alignment errors. *F1000Res.* **7**, 1860 (2018).
- 1047 30. Taylor, D. J. et al. Sources of gene expression variation in a globally diverse cohort. *bioRxiv*
- 1048 2023.11.04.565639 (2023) doi:10.1101/2023.11.04.565639.
- 1049 31. Bryois, J. *et al.* Cis and trans effects of human genomic variants on gene expression. *PLoS*1050 *Genet.* **10**. e1004461 (2014).
- 1051 32. Mountjoy, E. *et al.* An open approach to systematically prioritize causal variants and genes
- at all published human GWAS trait-associated loci. *Nat. Genet.* 1–7 (2021).
- 1053 33. Yin, X. *et al.* Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for
- 1054 systemic lupus erythematosus. Ann. Rheum. Dis. 80, 632–640 (2021).
- 34. King, E. A., Dunbar, F., Davis, J. W. & Degner, J. F. Estimating colocalization probability
 from limited summary statistics. *BMC Bioinformatics* 22, 254 (2021).
- 1057 35. Meuwissen, M. E. C. *et al.* Human USP18 deficiency underlies type 1 interferonopathy
- 1058 leading to severe pseudo-TORCH syndrome. J. Exp. Med. 213, 1163–1174 (2016).
- 1059 36. Alsohime, F. et al. JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency. N.
- 1060 Engl. J. Med. **382**, 256–265 (2020).
- 1061 37. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).

1062 38. de Lange, K. M. e	et al. Genome-wide association stud	y implicates immune activation of
----------------------------	-------------------------------------	-----------------------------------

- 1063 multiple integrin genes in inflammatory bowel disease. *Nat. Genet.* **49**, 256–261 (2017).
- 1064 39. Schnitzler, G. R. *et al.* Convergence of coronary artery disease genes onto endothelial cell
- 1065 programs. *Nature* 1–9 (2024).
- 40. Weeks, E. M. *et al.* Leveraging polygenic enrichments of gene features to predict genes
 underlying complex traits and diseases. *Nat. Genet.* 55, 1267–1276 (2023).
- 41. Mostafavi, S. *et al.* Parsing the Interferon Transcriptional Network and Its Disease
 Associations. *Cell* 164, 564–578 (2016).
- 42. Banchereau, R. *et al.* Personalized Immunomonitoring Uncovers Molecular Networks that
 Stratify Lupus Patients. *Cell* **165**, 551–565 (2016).
- 1072 43. Baechler, E. C. *et al.* Interferon-inducible gene expression signature in peripheral blood
- 1073 cells of patients with severe lupus. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 2610–2615 (2003).
- 1074 44. Jefferies, C. A. Regulating IRFs in IFN Driven Disease. *Front. Immunol.* **10**, 325 (2019).
- 1075 45. Honda, K., Takaoka, A. & Taniguchi, T. Type I interferon [corrected] gene induction by the
- 1076 interferon regulatory factor family of transcription factors. *Immunity* **25**, 349–360 (2006).
- 1077 46. Reshef, Y. A. *et al.* Detecting genome-wide directional effects of transcription factor binding
 1078 on polygenic disease risk. *Nat. Genet.* **50**, 1483–1493 (2018).
- 1079 47. Kerimov, N. et al. eQTL Catalogue 2023: New datasets, X chromosome QTLs, and
- 1080 improved detection and visualisation of transcript-level QTLs. *PLoS Genet.* **19**, e1010932
 1081 (2023).
- 1082 48. Li, H. et al. Identification of a Sjögren's syndrome susceptibility locus at OAS1 that
- 1083 influences isoform switching, protein expression, and responsiveness to type I interferons.
- 1084 *PLoS Genet.* **13**, e1006820 (2017).
- 1085 49. Banday, A. R. *et al.* Genetic regulation of OAS1 nonsense-mediated decay underlies
- 1086 association with COVID-19 hospitalization in patients of European and African ancestries.
- 1087 Nat. Genet. 54, 1103–1116 (2022).

- 1088 50. Zdrazil, B. et al. The ChEMBL Database in 2023: a drug discovery platform spanning
- multiple bioactivity data types and time periods. *Nucleic Acids Res.* 52, D1180–D1192
 (2024).
- 1091 51. Morand, E. F. *et al.* Trial of Anifrolumab in Active Systemic Lupus Erythematosus. *N. Engl.*1092 *J. Med.* 382, 211–221 (2020).
- 1093 52. Amaya-Uribe, L., Rojas, M., Azizi, G., Anaya, J.-M. & Gershwin, M. E. Primary
- 1094 immunodeficiency and autoimmunity: A comprehensive review. *J. Autoimmun.* 99, 52–721095 (2019).
- 1096 53. Schmidt, R. E., Grimbacher, B. & Witte, T. Autoimmunity and primary immunodeficiency:
 1097 two sides of the same coin? *Nat. Rev. Rheumatol.* 14, 7–18 (2017).
- 1098 54. Primary immunodeficiency or monogenic inflammatory bowel disease (Version 4.191).
- 1099 https://panelapp.genomicsengland.co.uk/panels/398/.
- 1100 55. Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus
- 1101 erythematosus. *Nat. Med.* **28**, 2124–2132 (2022).
- 1102 56. Müller Fabian *et al.* CD19 CAR T-Cell Therapy in Autoimmune Disease A Case Series
- 1103 with Follow-up. *N. Engl. J. Med.* **390**, 687–700 (2024).
- 1104 57. Akinbiyi, T., McPeek, M. S. & Abney, M. ADELLE: A global testing method for Trans-eQTL
 1105 mapping. *bioRxiv* 2024.02.24.581871 (2024) doi:10.1101/2024.02.24.581871.
- 1106 58. Dutta, D. *et al.* Aggregative trans-eQTL analysis detects trait-specific target gene sets in
- 1107 whole blood. *Nat. Commun.* **13**, 1–14 (2022).
- 1108 59. Wang, L., Babushkin, N., Liu, Z. & Liu, X. Trans-eQTL mapping in gene sets identifies
- 1109 network effects of genetic variants. *bioRxiv* 2022.11.11.516189 (2022)
- 1110 doi:10.1101/2022.11.11.516189.
- 1111 60. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O'Garra, A. Type I interferons in
- 1112 infectious disease. *Nat. Rev. Immunol.* **15**, 87–103 (2015).
- 1113 61. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium et al. The

- 1114 interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian
- 1115 randomisation analysis. *Lancet* **379**, 1214–1224 (2012).
- 1116 62. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) et al.
- 1117 Association between C reactive protein and coronary heart disease: mendelian
- 1118 randomisation analysis based on individual participant data. *BMJ* **342**, d548 (2011).
- 1119 63. Burgess, S. *et al.* Using genetic association data to guide drug discovery and development:
- 1120 Review of methods and applications. *Am. J. Hum. Genet.* **110**, 195–214 (2023).
- 1121 64. Zheng, J. et al. Phenome-wide Mendelian randomization mapping the influence of the
- 1122 plasma proteome on complex diseases. *Nat. Genet.* **52**, 1122–1131 (2020).
- 1123 65. Karim, M. A. *et al.* Systematic disease-agnostic identification of therapeutically actionable
- 1124 targets using the genetics of human plasma proteins. *medRxiv* (2023)
- 1125 doi:10.1101/2023.06.01.23290252.
- 1126 66. Wong, D. et al. Genomic mapping of the MHC transactivator CIITA using an integrated
- 1127 ChIP-seq and genetical genomics approach. *Genome Biol.* **15**, 494 (2014).
- 1128 67. Civelek, M. et al. Genetic Regulation of Adipose Gene Expression and Cardio-Metabolic
- 1129 Traits. Am. J. Hum. Genet. **100**, 428–443 (2017).
- 1130 68. Hore, V. *et al.* Tensor decomposition for multiple-tissue gene expression experiments. *Nat.*1131 *Genet.* 48, 1094–1100 (2016).
- 1132 69. Ntranos, V., Kamath, G. M., Zhang, J. M., Pachter, L. & Tse, D. N. Fast and accurate
- 1133 single-cell RNA-seq analysis by clustering of transcript-compatibility counts. *Genome Biol.*
- **11**34 **17**, 112 (2016).
- 1135 70. EQTLGen consortium. https://www.eqtlgen.org/.
- 1136 71. Morris, J. A. *et al.* Discovery of target genes and pathways at GWAS loci by pooled single1137 cell CRISPR screens. *Science* **380**, eadh7699 (2023).
- 1138 72. Weinstock, J. S. *et al.* Gene regulatory network inference from CRISPR perturbations in
- 1139 primary CD4+ T cells elucidates the genomic basis of immune disease. *bioRxiv*

1140 2023.09.17.557749 (2023) doi:10.1101/2023.09.17.557749.

- 1141 73. Boyd, A. *et al.* Cohort Profile: the 'children of the 90s'--the index offspring of the Avon
- 1142 Longitudinal Study of Parents and Children. Int. J. Epidemiol. 42, 111–127 (2013).
- 1143 74. Fraser, A. *et al.* Cohort Profile: the Avon Longitudinal Study of Parents and Children:
- 1144 ALSPAC mothers cohort. *Int. J. Epidemiol.* **42**, 97–110 (2013).
- 1145 75. Buil, A. et al. Gene-gene and gene-environment interactions detected by transcriptome
- 1146 sequence analysis in twins. *Nat. Genet.* **47**, 88–91 (2015).
- 1147 76. Firmann, M. *et al.* The CoLaus study: a population-based study to investigate the
- 1148 epidemiology and genetic determinants of cardiovascular risk factors and metabolic
- 1149 syndrome. *BMC Cardiovasc. Disord.* **8**, 6 (2008).
- 1150 77. Sönmez Flitman, R. et al. Untargeted Metabolome- and Transcriptome-Wide Association
- 1151 Study Suggests Causal Genes Modulating Metabolite Concentrations in Urine. J. Proteome
- 1152 *Res.* **20**, 5103–5114 (2021).
- 1153 78. Lappalainen, T. *et al.* Transcriptome and genome sequencing uncovers functional variation
 1154 in humans. *Nature* **501**, 506–511 (2013).
- 1155 79. Liang, L. *et al.* A cross-platform analysis of 14,177 expression quantitative trait loci derived
 1156 from lymphoblastoid cell lines. *Genome Res.* 23, 716–726 (2013).
- 1157 80. Gutierrez-Arcelus, M. *et al.* Passive and active DNA methylation and the interplay with
 1158 genetic variation in gene regulation. *Elife* 2, e00523 (2013).
- 1159 81. Theusch, E., Chen, Y.-D. I., Rotter, J. I., Krauss, R. M. & Medina, M. W. Genetic variants
- 1160 modulate gene expression statin response in human lymphoblastoid cell lines. BMC
- 1161 *Genomics* **21**, 555 (2020).
- 1162 82. Zhao, H. *et al.* CrossMap: a versatile tool for coordinate conversion between genome
 1163 assemblies. *Bioinformatics* **30**, 1006–1007 (2014).
- 1164 83. Byrska-Bishop, M. *et al.* High-coverage whole-genome sequencing of the expanded 1000
- 1165 Genomes Project cohort including 602 trios. *Cell* **185**, 3426–3440.e19 (2022).

- 1166 84. Deelen, P. *et al.* Genotype harmonizer: automatic strand alignment and format conversion
 1167 for genotype data integration. *BMC Res. Notes* **7**, 901 (2014).
- 1168 85. Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
- 1169 *Nature* **590**, 290–299 (2021).
- 1170 86. Das, S. et al. Next-generation genotype imputation service and methods. Nat. Genet. 48,
- 1171 1284–1287 (2016).
- 1172 87. Fuchsberger, C., Abecasis, G. R. & Hinds, D. A. minimac2: faster genotype imputation.
 1173 *Bioinformatics* 31, 782–784 (2015).
- 1174 88. Loh, P.-R. et al. Reference-based phasing using the Haplotype Reference Consortium
- 1175 panel. *Nat. Genet.* **48**, 1443–1448 (2016).
- 1176 89. Kerimov, N. *et al.* A compendium of uniformly processed human gene expression and
 1177 splicing quantitative trait loci. *Nat. Genet.* 53, 1290–1299 (2021).
- 1178 90. Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory
 1179 requirements. *Nat. Methods* 12, 357–360 (2015).
- 1180 91. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic
- 1181 features. *Bioinformatics* **26**, 841–842 (2010).
- 92. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy--analysis of Affymetrix GeneChip
 data at the probe level. *Bioinformatics* 20, 307–315 (2004).
- 1184 93. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
 1185 binary traits. *Nat. Genet.* 53, 1097–1103 (2021).
- 1186 94. Nica, A. C. *et al.* The architecture of gene regulatory variation across multiple human
- 1187 tissues: the MuTHER study. *PLoS Genet.* **7**, e1002003 (2011).
- 1188 95. Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. *Proc. Natl.*
- 1189 *Acad. Sci. U. S. A.* **100**, 9440–9445 (2003).
- 1190 96. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression
- analysis of RNA-seq data. *Genome Biol.* **11**, R25 (2010).

- 1192 97. Roshchupkin, G. V. *et al.* HASE: Framework for efficient high-dimensional association
- 1193 analyses. *Sci. Rep.* **6**, 36076 (2016).

1194 98. Seabold, S. & Perktold, J. Statsmodels: Econometric and statistical modeling with python.

- in *Proceedings of the 9th Python in Science Conference* (SciPy, 2010).
- 1196 doi:10.25080/majora-92bf1922-011.
- 1197 99. Huang, Y., McCarthy, D. J. & Stegle, O. Vireo: Bayesian demultiplexing of pooled single-
- 1198 cell RNA-seq data without genotype reference. *Genome Biol.* **20**, 273 (2019).
- 1199 100. Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e29
- 1200 (2021).
- 1201 101.McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor
- 1202 RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res.* 40, 4288–
 1203 4297 (2012).
- 1204 102.Kowalczyk, M. S. et al. Single-cell RNA-seq reveals changes in cell cycle and differentiation
- 1205 programs upon aging of hematopoietic stem cells. *Genome Res.* **25**, 1860–1872 (2015).
- 1206 103. Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell
- 1207 analysis. *Nat. Biotechnol.* **42**, 293–304 (2023).